Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
July 2026 — Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Laboratoires Herbolistique is a French natural health company specializing in the development, manufacturing and commercialization of premium plant-based dietary supplements. The company operates a distinctive prescription-driven direct-to-consumer (D2C) e-commerce model, supported by a network of more than 5,000 healthcare practitioners, including naturopaths, physicians and osteopaths. Laboratoires Herbolistique benefits from a fully integrated value chain. A recent vertical integration initiative, achieved through the acquisition of manufacturing capabilities, enabled the company to internalize approximately 80% of its production while creating additional capacity to develop its contract development and manufacturing organization (CDMO) business. In 2025, Laboratoires Herbolistique generated more than US$16 million in revenue and US$5 million in EBITDA.
Yotta Capital Partners is a French mission-driven private equity firm focused on industrial decarbonization. The firm backs innovative small- and mid-cap industrial companies through both buy-out and growth strategies with approximately US$460 million in assets under management.
Our role in the transaction
Oaklins’ team in France acted as the sell-side advisor to Laboratoires Herbolistique and its shareholders in this transaction. The team conducted a competitive process involving both private equity firms and corporate buyers for a majority stake. This transaction further strengthens Oaklins’ expertise in the food supplements sector and demonstrates its ability to identify the most suitable financial partners for each client’s strategic objectives.
Talk to the deal team
Related deals
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreCibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more